Endocrine and Metabolic Science · 2020 · 94 citations · 43 references
MedicineInternal MedicineNeurologyDiabetologyNeuromuscular DisordersNeuropathologyDiabetes MellitusDiabetic NeuropathyPeripheral Nerve DisordersPeripheral NeuropathiesPeripheral Neuropathy EvaluationDiabetic Neuropathy AssessmentNeuropathy Severity ScoringPeripheral Neuropathy Grading
The aim of this study was to assess the prevalence of diabetic peripheral neuropathy (DPN) and associated risk factors among patients with type 1 (T1D) and type 2 diabetes (T2D). A total of 141 patients with T1D and 844 patients with T2D mostly from primary care practices were enrolled in our register initiative. DPN was assessed using the Neuropathy Symptom Score (NSS) and Neuropathy Deficit Score (NDS). Data were analyzed by bivariate and multivariate logistic regression. The overall prevalence of DPN in the cohort was 40.3% [95% CI: 37.3-43.3%], 29.1% [22.0-36.9%] among patients with T1D and 42.2% [38.9-45.6%] with T2D (p<0.005). DPN prevalence increased with age from 11.9% [4.5-20.9%] aged ≤40 years up to >50% [47.7-57.5%] aged >70 years (p<0.001). The diabetes duration subclassification revealed a high DPN-prevalence of 35% [15.0-55.0%] among patients with T2D at time of diagnosis. A significant increase of prevalence was present 5 and 25 years following T1D and 25 years following T2D diagnosis (p<0.001). DPN risk factors were “older age” (OR [95% CI]: 1.05 [1.02-1.08], p<0.005) and loss of consciousness due to severe hypoglycemia episodes (OR [95% CI]: 10.28 [1.70-62.01], p<0.05) for T1D and “older age” (OR [95% CI]: 1.02 [1.00-1.04], p=0.056) and the presence of a cardiovascular-metabolic profile (obesity, hypertension, low HDL-c levels, elevated triglycerides, low physical activity and limited range of motion) for T2D. Furthermore, co-morbidities such as diabetic nephropathy (OR [95% CI]: 1.92 [1.14-3.22]), retinopathy (OR [95% CI]: 1.87 [1.10-3.18]) and peripheral artery disease (OR [95% CI]: 1.81 [1.07-3.08]) were independently associated with DPN (p<0.05). High rates of DPN among outpatients with diabetes suggest the need for early screening, especially in individuals that present with a plethora of co-morbidities. Diabetes treatment regimens that preclude a cardiovascular-metabolic risk profile and episodes of severe hypoglycemia should be sought, given that such episodes are more common among patients suffering from DPN.
43
Sarah H. Wild, Gojka Roglić, Anders Green et al. · Diabetes Care · 2004 · 15.3K citations
The metabolic syndrome—a new worldwide definition
K. G. M. M. Alberti, Paul Zimmet, Jonathan E. Shaw · The Lancet · 2005 · 9.3K citations
Vascular Risk Factors and Diabetic Neuropathy
Solomon Tesfaye, Nish Chaturvedi, Simon E.M Eaton et al. · New England Journal of Medicine · 2005 · 1.3K citations · Full text